Qi Qiao

Qi Qiao

Auto-generated profile, based on publicly available information

Qi Qiao

Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
QQQi Qiao
Qi Qiao
XLXiong Liu
Xiong Liu
TYTing Yang
Ting Yang
KCKexin Cui
Kexin Cui
LKLi Kong
Li Kong
ZZZhiping Zhang
Zhiping Zhang
Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air–blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.

3 January 2024 in ACS Nano
Verified
Journal Article
Closed access
XLXiaonan Li
Xiaonan Li
QQQi Qiao
Qi Qiao
XLXiong Liu
Xiong Liu
QHQian Hu
Qian Hu
YYYulin Yu
Yulin Yu
ZZZhiping Zhang
Zhiping Zhang

29 August 2022 in ACS Nano
Verified
Journal Article
Closed access
QQQi Qiao
Qi Qiao
XLXiong Liu
Xiong Liu
KCKexin Cui
Kexin Cui
XLXiaonan Li
Xiaonan Li
TTTianyi Tian
Tianyi Tian
ZZZhiping Zhang
Zhiping Zhang

26 June 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JCJae Young Choi
Jae Young Choi
QQQi Qiao
Qi Qiao
SHSe-Hoon Hong
Se-Hoon Hong
Chang Min KimChang Min Kim
Chang Min Kim
JJJAEHEE JEONG
JAEHEE JEONG
Hyun Ho ParkHyun Ho Park
Hyun Ho Park
Cell death-inducing DFF45-like effector (CIDE) domains, initially identified in apoptotic nucleases, form a family with diverse functions ranging from cell death to lipid homeostasis. Here we show that the CIDE domains of Drosophila and human apoptotic nucleases Drep2, Drep4, and DFF40 all form head-to-tail helical filaments. Opposing positively and negatively charged interfaces mediate the helical structures, and mutations on these surfaces abolish nuclease activation for apoptotic DNA fragmentation. Conserved filamentous structures are observed in CIDE family members involved in lipid homeostasis, and mutations on the charged interfaces compromise lipid droplet fusion, suggesting that CIDE domains represent a scaffold for higher-order assembly in DNA fragmentation and other biological processes such as lipid homeostasis.

4 August 2026 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SGSuyu Gao
Suyu Gao
YLYun Lu
Yun Lu
QQQi Qiao
Qi Qiao

1 September 2020 in Medical Mycology
Verified
Journal Article
Closed access
PDF file
QBQiao Biao
Qiao Biao
ZLZhang Lan-Fang
Zhang Lan-Fang
QQQiao Qi
Qiao Qi
NJNiu Jia-Hui
Niu Jia-Hui
RZRen Ze-Mei
Ren Ze-Mei
QLQingshan Li
Qingshan Li
Fungal growth-dependent gene coregulation is strongly implicated in alteration of gene-encoding target proteases ruling with an antifungal resistance niche and biology of resistant mutants. On the basis of multi-alterative processes in this platform, the resistance-modifying strategy is designed in ketoconazole resistant Candida albicans and evaluated with less selective Momordica charantia protein and allosterically phosphorylated derivatives at the Thr102, Thr24 and Thr255 sites, respectively. We demonstrate absolutely chemo-sensitizing efficacy regarding stepwise-modifying resistance in sensitivity, by a load of only 26.23–40.00 μg/l agents in Sabouraud's dextrose broth. Five successive modifying-steps realize the decreasing of ketoconazole E-test MIC50 from 11.10 to a lower level than 0.10 mg/l. With the ketoconazole resistance-modifying, colony undergoes a high-frequency morphological switch between high ploidy (opaque) and small budding haploid (white). A cellular event in the first modifying-step associates with relatively slow exponential growth (ie, a 4-h delay)-dependent action, mediated by agents adsorption. Moreover, multiple molecular roles are coupled with intracellularly and extracellularly binding to ATP-dependent RNA helicase dbp6; the 0.08–2.45 fold upregulation of TATA-box-binding protein, rRNA-processing protein and translation initiation factor 5A; and the 7.52–55.33% decrease of cytochrome P450 lanosterol 14α-demethylase, glucan 1, 3-β glucosidase, candidapepsin-1 and 1-acylglycerol-3-phosphate O-acyltransferase. Spatial and temporal gene coregulation, in the transcription and translation initiation stages with rRNA-processing, is a new coprocessing platform enabling target protease attenuations for resistance-impairing. An updated resistance-modifying measure of these agents in the low-dose antifungal strategic design may provide opportunities to a virtually safe therapy that is in high dose-dependency. A new platform to modify resistance is fungal growth-dependent gene coregulation. MAP30 and phosphorylated derivatives are candidate resistance-modifying agents. Low-dose stepwise treatment absolutely modifies azole resistance in model fungus.